Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a human vaccine and therapeutic biologics manufacturer, announced that it has submitted a Biologic License Application (BLA) for its LZ901 to the National Medical Products Administration (NMPA), which has been accepted for review.
Vaccine Details
LZ901 is a recombinant herpes zoster vaccine developed based on the crystallizable region of the glycoprotein E fragment of varicella zoster virus (VZV). The vaccine has a tetramer molecular structure and is designed to prevent herpes zoster caused by VZV.-Fineline Info & Tech
